Review of the in-vitro evaluation of FCE 22101.
FCE 22101 is a broad spectrum beta-lactam displaying bactericidal properties, stable to a wide range of clinically relevant beta-lactamases, and sharing with other beta-lactams a modest post-antibiotic effect and synergistic interactions with aminoglycosides. The ability to administer the drug by oral and parenteral routes suggests that it could be clinically useful.
Wise
R
R
Department of Medical Microbiology, Dudley Road Hospital, Birmingham, UK.
Ballard
R C
RC
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001426:Bacterial Proteins; D015780:Carbapenems; D002352:Carrier Proteins / Q000378:metabolism; D006602:Hexosyltransferases; D006801:Humans; D007769:Lactams; D008826:Microbial Sensitivity Tests; D002267:Muramoylpentapeptide Carboxypeptidase / Q000378:metabolism; D046915:Penicillin-Binding Proteins; D010458:Peptidyl Transferases
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015780:Carbapenems; D002352:Carrier Proteins; D007769:Lactams; D046915:Penicillin-Binding Proteins; C040033:ritipenem; D010458:Peptidyl Transferases; D006602:Hexosyltransferases; D002267:Muramoylpentapeptide Carboxypeptidase